Anti-tumour necrosis factor alpha (anti-TNF-α) inhibitors, such as infliximab and adalimumab, are commonly used to treat moderate to severe refractory IBD and fistulizing Crohn's disease. The gene discussed is TNF; the disease is Crohn disease.